Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 7/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215717 | 1.00 | GRIA2 (0.41) | GRIA2GRIA4KCNH2APP | |
| SCHEMBL2217489 | 1.00 | GRIA2 (0.41) | GRIA2GRIA4KCNH2APP | |
| SCHEMBL2186876 | 0.88 | GRIA2 (0.40) | GRIA2GRIA4KCNH2APP | |
| SCHEMBL2190143 | 0.88 | GRIA2 (0.40) | GRIA2GRIA4KCNH2APP | |
| SCHEMBL2186879 | 0.88 | GRIA2 (0.40) | GRIA2GRIA4KCNH2APP | |
| SCHEMBL2213771 | 0.86 | GRIA2 (0.32) | GRIA2KCNH2 | |
| SCHEMBL2213772 | 0.86 | GRIA2 (0.32) | GRIA2KCNH2 | |
| SCHEMBL2215739 | 0.86 | GRIA2 (0.32) | GRIA2KCNH2 | |
| SCHEMBL2217961 | 0.85 | GRIA2 (0.41) | GRIA2GRIA4KCNH2 | |
| SCHEMBL12435031 | 0.85 | GRIA2 (0.41) | GRIA2GRIA4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356099-A1 | TETRAHYDROFURANYL SULFONAMIDES FOR USE AS AMPA MODULATORS IN THE TREATMENT OF CNS DISORDERS | Pfizer Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110178165-A1 | TETRAHYDROFURANYL SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2011-07-21 | — | — | US | disclosed |
| WO-2010041162-A1 | TETRAHYDROFURANYL SULFONAMIDES FOR USE AS AMPA MODULATORS IN THE TREATMENT OF CNS DISORDERS | PFIZER INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178165-A1 | TETRAHYDROFURANYL SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, DHFR, SULT2A1 | GRIA2 1379/4885GRIA4 769/4885KCNH2 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.